The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials

Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic agents and immune checkpoint inhibitors. Ramucirumab, an anti-VEGFR2 antibody, has shown efficacy in GC, but the benefits are li...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Hematol Oncol
Egile Nagusiak: Saeed, Anwaar, Park, Robin, Sun, Weijing
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2021
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7802258/
https://ncbi.nlm.nih.gov/pubmed/33436042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01034-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak